Bayer Aktiengesellschaft

Bayer Aktiengellschaft

J&uuml;rgen Stoltefuss

Carsten Schmeck

Michael L&ouml;gers

Hilmar Bischoff

Delf Schmidt

Gunter Schmidt

Klaus-Dieter Bremm

Arndt Brandes

Arnold Paessens

Erwin Graef

Siegfried Goldmann

Paul Naab

Holger Paulsen

Stefan Lottmann

Karl-Heinz Schlemmer

Martin Bechem

Joachim Schuhmacher

Rolf Angerbauer

Klemens Lustig

Christoph Gerdes

Stefan Antons

Olaf Weber

Michael Sperzel

Ulrich Niew&ouml;hner

Henry Giera

Ulrich Nielsch

Michael Conrad

J&ouml;rn St&ouml;lting

Gabriele Br&auml;unlich

Karl Deres

Stephan Nicholas M&uuml;ller

Matthias M&uuml;ller-Gliemann

Werner St&uuml;rmer

Stefan Lettmann

Thomas Kr&auml;mer

Siegfired Goldmann

Tetrahydroquinolinyl 6-methyldihydrothiadiazinone derivatives and use thereof

Dihydropyrimidines

Substituted tetrahydro-naphthalenes and analogous compounds are prepared by reducing or condensing appropriate functional substituents in substituted tetrahydro-naphthalenes and analogous compounds by customary methods and converting functional groups in this manner into the desired groups. The compounds according to the invention are suitable for use as active compounds in pharmaceuticals, in particular in pharmaceuticals for treating arteriosclerosis and also dyslipidaemias.

Substituted tetrahydronaphthaline and analogous compounds

The tetrahydroquinolines can be prepared by condensing appropriately substituted tetrahydroquinoline aldehydes with suitable substances and subsequently varying the substituents present by customary methods. The tetrahydroquinolines are suitable as active compounds in medicaments, in particular in medicaments. for the treatment of arteriosclerosis and dyslipidaemias.

4-phenyltetrahydrochinoline utilized as an inhibitor of the cholesterol ester transfer protein

The invention relates to new 2-heterocyclically substituted dihydropyrimidines, medicaments which contain these 2-heterocyclically substituted dihydropyrimidines, and a process for preparation of medicaments. The invention furthermore relates to the use of the 2-heterocyclically substituted dihydropyrimidines for the production of a medicament, in particular for the treatment of acute or chronic viral diseases, in particular for the production of a medicament for the treatment of acute or chronic hepatitis B infections.

2-heterocyclically substituted dihydropyrimidines

Use of dihydropyrimidines as medicaments, and novel substances

Hetero-tetrahydroquinolines can be prepared either by condensing correspondingly substituted hetero-tetrahydroquinoline aldehydes with the desired substituent or by reducing the corresponding keto-substituted hetero-tetrahydroquinolines, followed by introduction of the desired substituent by customary methods. The hetero-tetrahydroquinolines are suitable for use as active compounds in medicaments, in particular in medicaments for treating artheriosclerosis and dyslipidaemias.

4-heteroaryl-tetrahydroquinolines and their use as inhibitors of the cholesterin-ester transfer protein

The tetrahydroquinolines can be prepared by condensing appropriately substituted tetrahydroquinoline aldehydes with suitable substances and subsequently varying the substituents present by customary methods. The tetrahydroquinolines are suitable as active compounds in medicaments, in particular in medicaments for the treatment of arteriosclerosis and dyslipidaemias.

Tetrahydroquinolines, processes for their preparation, pharmaceutical compositions containing them, and their use to prevent or treat hyperlipoproteinaemia

The cycloalkano-pyridines are prepared by reacting corresponding cycloalkano-pyridine-aldehydes with suitable organometallic compounds or Wittig or Grignard reagents or reacting compounds of the cycloalkano-pyridine alcohols type with suitable bromine compounds, and optionally varying the functional groups accordingly. The cycloalkanopyridines are suitable as active compounds in medicaments, in particular in medicaments for the treatment of hypertipoproteinaemia and arteriosclerosis.

Cycloalkano-pyridines

Growing community of inventors

Haan, Germany

Jürgen Stoltefuss

Growing community of inventors

Haan, Germany

J&uuml;rgen Stoltefuss

Jürgen Stoltefuss